Three platforms just closed some of the biggest rounds of the half, and a single Medicare policy decision is a big part of the reason.
Weight management had a standout funding half, and the timing lines up closely with a specific change in how GLP-1s get reimbursed for millions of Medicare beneficiaries.
Three rounds, one underlying cause
eMed ($200M), Nourish ($100M) and Midi Health ($100M) all closed rounds of $100M or more in H1 2026, anchoring weight management as the second-highest funded clinical indication of the half, according to Rock Health.
That $400M across three companies works out to more than 5% of the entire half-year's $7.4B digital health total. Medicare's GLP-1 Bridge, live since July 1, caps eligible beneficiaries' cost at $50 a month, covers Wegovy, and reaches an estimated 3.8M beneficiaries through December 2027, while notably excluding the diabetes-indicated Ozempic and Mounjaro from that same copay structure.
Adjacent peptide platforms are drawing capital on the strength of this same infrastructure buildout, discussed in the next article, a sign that investors see the GLP-1 reimbursement shift as opening a broader metabolic and longevity opportunity, not just a single-drug one.
Funding followed the policy, not the other way around
A $50 monthly copay removes the price objection that has historically kept many patients from starting or staying on treatment, which shifts the competitive battle to adherence and coaching, exactly the layer these three platforms operate in.
This is not a coincidence of timing. Investors are backing the companies positioned to capture a wave of newly price-qualified Medicare beneficiaries who now need ongoing coaching and follow-up, not just a prescription, to stay on treatment.
The reimbursement change effectively created the customer acquisition opportunity these three rounds are underwriting, and the size of the checks reflects how large that newly addressable population actually is.
Who's left out of the $50 line
Watch how quickly these three platforms, and any fast followers, move to capture the beneficiaries the Bridge is bringing into treatment.
Also watch whether platforms serving the excluded diabetes population find a different reimbursement argument, since that population is currently left out of the $50 copay structure entirely and represents a real, underserved opportunity for whoever solves it first. A startup that cracks a comparable reimbursement pathway for the diabetes-indicated drugs would be addressing a population at least as large as the one the Bridge currently covers.
